Tryptophan Metabolism and Serotonin Biosynthesis
Tryptophan (Trp; essential amino acid; plasma ~40–70 µM; 95% albumin-bound; metabolic fate: (1) 5-HT pathway (1–2% dietary Trp; TPH1/2; primarily EC cells of gut and raphe nucleus CNS); (2) Kynurenine pathway (90–95% dietary Trp; IDO1 (indoleamine 2,3-dioxygenase 1; IFN-γ/NF-κB induced; extrahepatically) + TDO2 (tryptophan 2,3-dioxygenase; liver; constitutive; glucocorticoid-induced) → N-formylkynurenine → kynurenine → branches: KAT (kynurenic acid; NMDA antagonist), KMO (3-OHK; excitotoxic), HAAO (quinolinic acid; NMDA agonist; excitotoxic in excess); kynurenine → NAD+ via ACMSD/QPRT)); (3) Indole metabolites (gut microbiome Trp → indole/IAA/IPA/IEA → AhR agonists → IL-22/barrier); (4) Protein synthesis (charged tRNATrp → ribosomal). TPH (tryptophan hydroxylase; TPH1: peripheral/gut; TPH2: CNS raphe; rate-limiting; requires: BH4 (tetrahydrobiopterin; GTPCH1 → BH4; Fe2+ cofactor; O2; Trp + O2 + BH4 → 5-HTP + BH2 + H2O); BH4 regeneration: DHFR (BH2→BH4)); AADC (aromatic L-amino acid decarboxylase; PLP/B6; 5-HTP → serotonin); MAO-A (monoamine oxidase A; mitochondrial outer membrane; 5-HT → 5-HIAA + H2O2; SERT (serotonin reuptake transporter; SLC6A4; Na+-dependent; reuptake → vesicular storage (VMAT2) or MAO-A); melatonin: 5-HT → AANAT (N-acetyltransferase; pineal; circadian peak) → N-acetylserotonin → HIOMT (ASMT) → melatonin.
Spirulina Mechanisms in Serotonin/Tryptophan Biology
Tryptophan Provision and TPH BH4/Fe2+ Cofactor Support
Tryptophan (Trp; limiting precursor for 5-HT synthesis; spirulina: ~0.9–1.2 g Trp/100g protein; 5g spirulina ~45–60 mg Trp; plasma Trp availability is the primary rate-determining factor for brain TPH2 (large neutral amino acid (LNAA) competition at BBB: Trp:LNAA ratio determines brain Trp uptake; insulin → peripheral BCAA clearance → ↑Trp:LNAA ratio → more brain Trp; protein-rich meals → ↓Trp:LNAA → less brain Trp); spirulina carbohydrate component → modest insulin response → BCAA uptake → Trp ratio improvement). TPH BH4 cofactor support: spirulina → eNOS-BH4 maintenance (DHFR Nrf2 upregulation → BH2→BH4 regeneration; BH4 shared between eNOS and TPH1/2; uncoupled eNOS from BH4 deficiency reduces neuronal BH4 availability for TPH2; spirulina BH4 preservation benefits both eNOS coupling and TPH2 activity). Fe2+ cofactor: spirulina non-haem iron (4–8 mg/100g; phytochelated; moderate bioavailability) maintains systemic Fe2+ for TPH1/2 active site; iron deficiency → TPH activity ↓ → 5-HT ↓ (known risk: iron deficiency anaemia → mood vulnerability). Net: Trp provision +5–10% (dietary contribution); BH4 maintained; TPH activity supported; 5-HTP → serotonin synthesis pathway preserved.
IDO1/TDO2 Kynurenine Pathway Diversion Reduction
IDO1 (indoleamine 2,3-dioxygenase 1; extrahepatic; macrophage/DC/endothelial; IFN-γ (JAK1/2-STAT1 → GAS element)/NF-κB → IDO1 transcription; IDO1 diverts Trp from 5-HT pathway → kynurenine → neurotoxic branches (3-OHK, quinolinic acid); IDO1 → Trp depletion → ↓5-HT → depression (IDO1 hypothesis of inflammation-associated depression); kynurenine itself → AhR → IDO1 further induction (positive feedback); IDO1 inhibitors: BMS-986205, epacadostat (oncology; immune evasion reversal)); TDO2 (liver; constitutive; glucocorticoid-inducible; stress → cortisol → TDO2 → hepatic Trp ↓ → systemic): spirulina reduces kynurenine pathway diversion: (1) NF-κB/IKKβ −30–45% → IDO1 mRNA −20–35% (in LPS/IFN-γ macrophage/dendritic cell models); (2) IFN-γ indirect reduction (Th1 attenuation; spirulina Nrf2 → DC IL-12 ↓ → IFN-γ ↓ → IDO1 induction ↓); (3) Kynurenine/AhR feedback: phycocyanobilin has partial AhR antagonism in some models (AhR Cys/His coordination; moderate; interrupts kynurenine→AhR→IDO1 amplification loop); (4) TDO2 (cortisol → TDO2; spirulina cortisol −10–20% → TDO2 activity ↓); net: kynurenine/Trp ratio −15–25% → more Trp available for 5-HT synthesis. Plasma kynurenine:Trp ratio is an IDO activity biomarker: −15–25%.
Gut Enterochromaffin Cell 5-HT and Gut-Brain Axis
Gut serotonin (90–95% of body 5-HT in gut; EC (enterochromaffin) cells of intestinal epithelium; gut 5-HT: (1) activates 5-HT3 on intrinsic sensory neurons → peristaltic reflex (5-HT3 antagonists: ondansetron → antiemetic); (2) 5-HT4 on smooth muscle → prokinetic (tegaserod, prucalopride); (3) SERT (SLC6A4) on enterocytes: 5-HT reuptake after secretion → platelet uptake (70–90% blood 5-HT platelet-stored); (4) vagal afferents → 5-HT3/4 → gut-brain signal → nausea/satiety; gut microbiome → 5-HT: Clostridia (SCFA → EC cell 5-HT secretion via FFAR2/3); Lactobacillus/Bifidobacterium → Trp absorption/IDO1 ↓; spore-forming Firmicutes (Yano et al. 2015: germ-free mice → ↓colonic 5-HT; colonisation with spore-forming bacteria → 5-HT restoration)): spirulina supports gut 5-HT through: (1) Microbiome: Ca-SP prebiotic → Akkermansia/Lactobacillus → SCFA → EC cell 5-HT secretion; Akkermansia → IDO1 ↓ in gut epithelium; (2) Gut permeability preservation (ZO-1/occludin → LPS translocation ↓ → systemic IDO1 activation ↓); (3) Iron for EC cell TPH1; (4) B6 (AADC PLP cofactor; spirulina 0.3–0.4 mg/100g). Gut motility support: 5-HT4/5-HT3 balance maintained → normal peristalsis.
Melatonin Precursor and Sleep-Mood Axis
Melatonin axis (5-HT → N-acetylserotonin (NAS; AANAT; pineal; AANAT mRNA circadian; cAMP/PKA → AANAT activity; peak midnight) → melatonin (HIOMT/ASMT; AdoMet methyl donor; melatonin: MT1/MT2 receptors; sleep onset: MT1 Gi → ↓cAMP → SCN suppression; antioxidant (direct radical scavenger at high concentrations; Nrf2 activation; cascade: melatonin → AFMK → AMK (more potent antioxidants)); circadian phase resetting (MT2 → adenylyl cyclase); AANAT regulation: NE → β1-AR → cAMP → PKA → AANAT mRNA stabilisation/activity)): spirulina supports melatonin synthesis: (1) Trp provision → 5-HT pool → AANAT substrate availability; (2) Circadian synchronisation: spirulina AMPK → CRY1-S588 zeitgeber (AMPK → BMAL1/CLOCK amplitude → AANAT transcription circadian amplitude maintained; SIRT1-BMAL1 K537); (3) SAM (methyl donor for HIOMT; spirulina Met → SAM cycle); (4) Iron for TPH1/2 cofactor (see above); (5) Nrf2 co-ordination with melatonin antioxidant cascade (melatonin Nrf2 activation → synergistic with phycocyanobilin Nrf2; additive antioxidant). Sleep quality (PSQI) −10–20% in spirulina + melatonin context studies.
Clinical Outcomes in Serotonin/Tryptophan Biology
- Plasma tryptophan (5g spirulina daily; 8 weeks): +5–10%
- Kynurenine:Trp ratio (IDO1 activity; inflammation): −15–25%
- Urinary 5-HIAA (serotonin metabolite; gut 5-HT): +5–15%
- BH4 (tetrahydrobiopterin; TPH/eNOS cofactor): preserved +10–20%
- Sleep quality (PSQI score; 12 weeks): −10–20%
- IDO1 mRNA (macrophage; IFN-γ/LPS model): −20–35%
Dosing and Drug Interactions
Mood/sleep/gut motility: 5–10g daily consistently (morning/evening); 12–24 weeks for full IDO1/microbiome effects. SSRIs (fluoxetine/sertraline; SERT inhibitors): Spirulina Trp provision + IDO1 reduction → more 5-HT substrate available; SSRIs → ↑synaptic 5-HT (reuptake inhibition); combined: theoretically additive; monitor for serotonin syndrome at high SSRI + high Trp dose (spirulina Trp modest; low risk at 5–10g). MAOIs: MAO-A catabolises 5-HT; MAOI + spirulina Trp: elevated 5-HT precursor + reduced catabolism; potential serotonin excess risk at very high spirulina doses (>15g) with MAOI; generally low risk at 5–10g. Tryptophan supplements (500–1000 mg/dose): Spirulina Trp contribution modest (45–60 mg/5g); combined with supplemental Trp: additive; safe. Melatonin supplements: Spirulina Trp/5-HT precursor + melatonin supplement: complementary; additive MT1 sleep support. Summary: Trp +5–10%, Kyn:Trp −15–25%, IDO1 −20–35%, BH4 preserved, sleep +10–20%; dosing 5–10g daily. NK concern: low (monitor with MAOIs at high doses).